NXL103
NXL103
NXL103 (pronounced en-ex-el-one-zero-three) is a novel antibiotic developed for the treatment of bacterial infections. It is a streptogramin antibiotic, which is a class of antibiotics that inhibit bacterial protein synthesis.
Etymology
The term "NXL103" is a proprietary name given by the pharmaceutical company Novexel, which developed the drug. The "NXL" stands for Novexel, and "103" is a sequential number assigned to the drug during its development.
Mechanism of Action
NXL103 works by inhibiting the protein synthesis of bacteria, thereby preventing their growth and multiplication. It does this by binding to the bacterial ribosome, a key component in the protein synthesis process.
Related Terms
- Antibiotic: A type of drug used to treat bacterial infections.
- Streptogramin: A class of antibiotics that inhibit bacterial protein synthesis.
- Protein synthesis: The process by which cells make proteins.
- Ribosome: A cellular structure that is the site of protein synthesis.
- Bacterial infection: An infection caused by bacteria.
See Also
External links
- Medical encyclopedia article on NXL103
- Wikipedia's article - NXL103
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski